{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:32:16Z","timestamp":1791685936696,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201510157C"],"award-info":[{"award-number":["HHSF223201510157C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201310144C"],"award-info":[{"award-number":["HHSF223201310144C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejps.2018.01.039","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T16:37:54Z","timestamp":1520354274000},"page":"258-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach"],"prefix":"10.1016","volume":"115","author":[{"given":"Bart","family":"Hens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marival","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Gonzalez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gislaine","family":"Kuminek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Benninghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00edr","family":"Rodr\u00edguez-Hornedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon L.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.01.039_bb0005","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1021\/mp4003915","article-title":"Molecular dynamics of the supercooled pharmaceutical agent posaconazole studied via differential scanning calorimetry and dielectric and mechanical spectroscopies","volume":"10","author":"Adrjanowicz","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jps.22750","article-title":"Supersaturating drug delivery systems: fast is not necessarily good enough","volume":"101","author":"Augustijns","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/mp100377m","article-title":"Excipient-mediated supersaturation stabilization in human intestinal fluids","volume":"8","author":"Bevernage","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation-permeation interplay: supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2012.11.026","article-title":"Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues","volume":"453","author":"Bevernage","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0035","first-page":"217","article-title":"Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions","volume":"63","author":"Brewster","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2018.01.039_bb0040","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2017.04.029","article-title":"Gastrointestinal behavior of itraconazole in humans - part 1: supersaturation from a solid dispersion and a cyclodextrin-based solution","volume":"525","author":"Brouwers","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1211\/002235702847","article-title":"Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method","volume":"55","author":"Buchwald","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.01.039_bb0055","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s11095-010-0213-8","article-title":"Predicting intestinal precipitation\u2014a case example for a basic BCS class II drug","volume":"27","author":"Carlert","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.01.039_bb0060","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1021\/mp300224h","article-title":"In vivo dog intestinal precipitation of mebendazole: a basic BCS class II drug","volume":"9","author":"Carlert","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0065","first-page":"1","article-title":"Oral bioavailability enhancement through supersaturation: an update and meta-analysis","author":"Fong","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ejps.2018.01.039_bb0070","series-title":"Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations","author":"Food & Drug Administration","year":"1997"},{"key":"10.1016\/j.ejps.2018.01.039_bb0075","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food & Drug Administration","year":"2001"},{"key":"10.1016\/j.ejps.2018.01.039_bb0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1208\/s12248-012-9389-7","article-title":"Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs","volume":"14","author":"Gao","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2018.01.039_bb0085","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3109\/03639045.2015.1054833","article-title":"In vitro-in vivo correlations: general concepts, methodologies and regulatory applications","volume":"41","author":"Gonz\u00e1lez-Garc\u00eda","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0090","series-title":"A \u2018Spring and Parachute\u2019 Approach to Designing Solid Celecoxib Formulations Having Enhanced Oral Absorption","author":"Guzm\u00e1n","year":"2004"},{"key":"10.1016\/j.ejps.2018.01.039_bb0095","series-title":"Textbook of Gastroenterology","first-page":"207","article-title":"The physiology of gastric motility and gastric emptying","author":"Hasler","year":"2008"},{"key":"10.1016\/j.ejps.2018.01.039_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejps.2014.07.008","article-title":"Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools","volume":"63","author":"Hens","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0105","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/jps.24690","article-title":"Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0110","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.xphs.2016.03.027","article-title":"Gastrointestinal and systemic monitoring of Posaconazole in humans after fasted and fed state Administration of a Solid Dispersion","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0115","first-page":"79","article-title":"Exploring gastrointestinal variables affecting drug and formulation behavior: methodologies, challenges and opportunities","volume":"59","author":"Hens","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0120","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1021\/acs.molpharmaceut.7b00396","article-title":"In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole","volume":"14","author":"Hens","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0125","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1021\/acs.molpharmaceut.7b00426","article-title":"Low buffer capacity and alternating motility along the human gastrointestinal tract: implications for in vivo dissolution and absorption of Ionizable drugs","volume":"14","author":"Hens","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0130","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1007\/s11095-012-0759-8","article-title":"pH-Induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties","volume":"29","author":"Hsieh","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.01.039_bb0135","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1021\/acs.molpharmaceut.5b00056","article-title":"pH-dependent liquid\u2013liquid phase separation of highly supersaturated solutions of weakly basic drugs","volume":"12","author":"Indulkar","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0140","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1021\/mp500201s","article-title":"Impact of polymers on the precipitation behavior of highly supersaturated aqueous danazol solutions","volume":"11","author":"Jackson","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0145","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.04223-14","article-title":"Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2018.01.039_bb0150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1208\/s12248-015-9816-7","article-title":"Comparison of deconvolution-based and absorption modeling IVIVC for extended release formulations of a BCS III drug development candidate","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2018.01.039_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1211\/0022357022511","article-title":"Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine","volume":"56","author":"Kostewicz","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.01.039_bb0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0165","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijpharm.2016.10.018","article-title":"In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT","volume":"515","author":"Kourentas","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.08.123","article-title":"Supersaturating drug delivery systems: the potential of co-amorphous drug formulations","volume":"532","author":"Laitinen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jcis.2008.05.034","article-title":"Nucleation and crystal growth in supersaturated solutions of a model drug","volume":"325","author":"Lindfors","year":"2008","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0185","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1021\/acs.molpharmaceut.5b00111","article-title":"Cocrystal transition points: role of cocrystal solubility, drug solubility, and solubilizing agents","volume":"12","author":"Lipert","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0190","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.2042-7158.2010.01030.x","article-title":"Pharmaceutical applications of cyclodextrins: basic science and product development","volume":"62","author":"Loftsson","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2018.01.039_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajps.2016.10.002","article-title":"Biorelevant test for supersaturable formulation","volume":"12","author":"Lu","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0200","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1021\/acs.molpharmaceut.5b00135","article-title":"In vitro dissolution of fluconazole and dipyridamole in gastrointestinal simulator (GIS), predicting in vivo dissolution and drug-drug interaction caused by acid-reducing agents","volume":"12","author":"Matsui","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0205","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.xphs.2016.02.020","article-title":"The evaluation of in vitro drug dissolution of commercially available oral dosage forms for Itraconazole in gastrointestinal simulator with biorelevant media","volume":"105","author":"Matsui","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0210","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acs.molpharmaceut.6b01063","article-title":"Utilization of gastrointestinal simulator, an in vivo predictive dissolution methodology, coupled with computational approach to forecast oral absorption of dipyridamole","volume":"14","author":"Matsui","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0215","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240\u202fmL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0220","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/acs.molpharmaceut.7b00095","article-title":"Magnetic resonance imaging quantification of fasted state colonic liquid pockets in healthy humans","volume":"14","author":"Murray","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0225","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1021\/mp400658k","article-title":"Effect of precipitation inhibitors on indomethacin supersaturation maintenance: mechanisms and modeling","volume":"11","author":"Patel","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0230","first-page":"110","article-title":"Analysis of Fickian and non-Fickian drug release from polymers","volume":"60","author":"Peppas","year":"1985","journal-title":"Pharm. Acta Helv."},{"key":"10.1016\/j.ejps.2018.01.039_bb0235","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/mp100116g","article-title":"Use of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variability","volume":"7","author":"Polster","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0240","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2018.01.039_bb0245","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jps.24423","article-title":"Trends in the precipitation and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation","volume":"104","author":"Raina","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0250","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1021\/js980490h","article-title":"Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems","volume":"88","author":"Rodr\u00edguez-Hornedo","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0255","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1021\/mp800114k","article-title":"PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs","volume":"5","author":"Rodr\u00edguez-Spong","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejpb.2016.09.014","article-title":"Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers","volume":"109","author":"Rubbens","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0265","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2018.01.039_bb0270","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.xphs.2016.04.036","article-title":"Assessing supersaturation and its impact on in vivo bioavailability of a low-solubility compound ABT-072 with a dual pH, two-phase dissolution method","volume":"105","author":"Shi","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2015.01.001","article-title":"Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies","volume":"90","author":"Stappaerts","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0280","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1021\/mp400439q","article-title":"Evolution of supersaturation of amorphous pharmaceuticals: the effect of rate of supersaturation generation","volume":"10","author":"Sun","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0285","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.xphs.2016.03.024","article-title":"Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems","volume":"105","author":"Sun","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0290","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","article-title":"The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC","volume":"57","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0295","article-title":"The combination of GIS and biphasic to better predict in vivo dissolution of BCS class IIb drugs, ketoconazole and raloxifene","author":"Tsume","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0300","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2017.02.042","article-title":"The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: gastrointestinal simulator (GIS)","volume":"102","author":"Tsume","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.01.039_bb0305","first-page":"2346","article-title":"The two-step mechanism of nucleation of crystals in solution","volume":"2","author":"Vekilov","year":"2010","journal-title":"Nano"},{"key":"10.1016\/j.ejps.2018.01.039_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1099-081X(200001)21:1<1::AID-BDD207>3.0.CO;2-D","article-title":"Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach","volume":"21","author":"Veng-Pedersen","year":"2000","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2018.01.039_bb0315","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2015.11.048","article-title":"Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms","volume":"498","author":"Verwei","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2018.01.039_bb0325","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.05.013","article-title":"Drug precipitation inhibitors in supersaturable formulations","volume":"453","author":"Xu","year":"2013","journal-title":"Int. J. of Pharm."},{"key":"10.1016\/j.ejps.2018.01.039_bb0330","series-title":"Identification and Quantitative Analysis of Posaconazole API in Noxafil\u00ae Oral Suspension. Presented at the 10\u03bf \u03a0\u0391\u039d\u0395\u039b\u039b\u0397\u039d\u0399\u039f \u0395\u03a0\u0399\u03a3\u03a4\u0397\u039c\u039f\u039d\u0399\u039a\u039f \u03a3\u03a5\u039d\u0395\u0394\u03a1\u0399\u039f \u03a7\u0397\u039c\u0399\u039a\u0397\u03a3 \u039c\u0397\u03a7\u0391\u039d\u0399, Patras, Greece","first-page":"6","author":"Zografos","year":"2015"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718300538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718300538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:44:55Z","timestamp":1565311495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718300538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":66,"alternative-id":["S0928098718300538"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.01.039","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}